On Wednesday, Dexcom got an upgrade to its Relative Strength (RS) Rating, from 78 to 86.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
IBD's proprietary RS Rating tracks market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
History shows that the market's biggest winners tend to have an RS Rating north of 80 in the early stages of their moves.
Looking For Winning Stocks? Try This Simple Routine
Is Dexcom Stock A Buy?
Dexcom stock has been rallying in recent weeks, retaking its 200-day moving average. It's not currently showing a potential entry point. See if the stock goes on to form a chart pattern that could spark a new run. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
The medical products maker reported -25% earnings growth last quarter. Revenue gains came in at 23%. The next quarterly numbers are expected on or around Apr. 29.
Dexcom stock holds the No. 3 rank among its peers in the Medical-Products industry group. Lantheus and Dexcom are also among the group's highest-rated stocks.
